In particular, a single dose of 25 μg·kg−1 of TCDD reduced the colitis symptoms through the activation of the AhR pathway, leading to a differential expression of the pathology-involved genes, i.e., Foxp3 and IL-17. This evidence concerns the gene IL17A and colitis.